[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.] #  @mike98572986 mike mike posts on X about $clpt, aav, approved, $rgnx the most. They currently have XXX followers and XX posts still getting attention that total XXX engagements in the last XX hours. ### Engagements: XXX [#](/creator/twitter::1422364980339380240/interactions)  - X Week XXXXX -XX% - X Month XXXXXX +463% - X Months XXXXXX +53% - X Year XXXXXX +4,407% ### Mentions: X [#](/creator/twitter::1422364980339380240/posts_active)  ### Followers: XXX [#](/creator/twitter::1422364980339380240/followers)  - X Week XXX +3.40% - X Month XXX +30% - X Months XXX +111% - X Year XXX +190% ### CreatorRank: XXXXXXXXX [#](/creator/twitter::1422364980339380240/influencer_rank)  ### Social Influence [#](/creator/twitter::1422364980339380240/influence) --- **Social category influence** [stocks](/list/stocks) [finance](/list/finance) **Social topic influence** [$clpt](/topic/$clpt), [aav](/topic/aav), [approved](/topic/approved), [$rgnx](/topic/$rgnx), [$qure](/topic/$qure), [novartis](/topic/novartis) **Top assets mentioned** [Novartis AG (NVS)](/topic/novartis) ### Top Social Posts [#](/creator/twitter::1422364980339380240/posts) --- Top posts by engagements in the last XX hours "Really good article on how difficult getting a drug approved is one of the below links should work If anything the hard problems have grown harder as the full complexity of biology has come into focus. We have more things to worry about than we used to says Lowe. By the time a drug reaches trials it represents a billion dollars and a decade in the lives of hundreds if not thousands of scientists. One patient signs up. Then two. Months pass. Time crawls. The meter is always running Satler says. Its so expensive. If were doing this right if were building a learning system the next XX drugs"  [@mike98572986](/creator/x/mike98572986) on [X](/post/tweet/1945909582431494177) 2025-07-17 18:12:52 UTC XXX followers, XXX engagements "$clpt $qure $rgnx Very good post by James Wilson big difference between those programs and the above companies the above companies are doing exactly this This contrasts with the relatively good safety profile of the broader portfolio of AAV products that deliver lower doses of systemic vector or use localized routes of administration. Overall low doses direct delivery As doctor Nicole Paulk has said Low doses + local admin = the way"  [@mike98572986](/creator/x/mike98572986) on [X](/post/tweet/1944904778636779711) 2025-07-14 23:40:08 UTC XXX followers, 2689 engagements "At the end of the day best thing we can all do is stay humble this game is extremely hard if Novartis can spend a billion dollars upfront and a couple months later find out that drug is likely useless do I believe that I can do the due diligence of a company like them Definitely not it is a perfect example of how tough biotech truly is. All each individual can do is what they are comfortable with understand the risks and go from there. I think anyone that has extreme confidence in anything is likely fooling ourselves. All we can do is make bets that make sense to each individual and live with"  [@mike98572986](/creator/x/mike98572986) on [X](/post/tweet/1945901343904047506) 2025-07-17 17:40:08 UTC XXX followers, XXX engagements "$clpt Bayer and Askbio For too long neurological and neurodegenerative diseases have been significantly underfunded despite the fact that they stand above cardiovascular disease as the top contributor to the global disease burden. In Europe brain disorders account for approximately XX% of the total disease burden and disorders of the nervous system are the largest cause of disability yet less than XX% of the total biomedical research budget is allocated to neurological research"  [@mike98572986](/creator/x/mike98572986) on [X](/post/tweet/1945609909762232795) 2025-07-16 22:22:04 UTC XXX followers, XXX engagements "$clpt Roche/Spark therapeutics study new research paper using clearpoint Overall the findings of this study will help guide the selection of the best retrograde AAV capsid for treatment of specific brain diseases. Vector was delivered into the bilateral putamen using intra-MRI guidance and the SmartFlow Neuro Cannula ClearPoint Neuro; Solano Beach CA Recent advances in neuroimaging techniques have helped delineate the structural and functional connectivity of the human brain and indicated that neurodegenerative diseases tend to target specific brain networks damaging their function.rAAV gene"  [@mike98572986](/creator/x/mike98572986) on [X](/post/tweet/1945531747992834445) 2025-07-16 17:11:29 UTC XXX followers, XXX engagements "Or we can also argue if there is another drug for hd that is coming out very near term that will be a threat (better numbers easier to do etc) that would be another good bear thesis imo"  [@mike98572986](/creator/x/mike98572986) on [X](/post/tweet/1945890080939471223) 2025-07-17 16:55:22 UTC XXX followers, XXX engagements
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
@mike98572986 mike
mike posts on X about $clpt, aav, approved, $rgnx the most. They currently have XXX followers and XX posts still getting attention that total XXX engagements in the last XX hours.
Engagements: XXX #
- X Week XXXXX -XX%
- X Month XXXXXX +463%
- X Months XXXXXX +53%
- X Year XXXXXX +4,407%
Mentions: X #
Followers: XXX #
- X Week XXX +3.40%
- X Month XXX +30%
- X Months XXX +111%
- X Year XXX +190%
CreatorRank: XXXXXXXXX #
Social Influence #
Social category influence stocks finance
Social topic influence $clpt, aav, approved, $rgnx, $qure, novartis
Top assets mentioned Novartis AG (NVS)
Top Social Posts #
Top posts by engagements in the last XX hours
"Really good article on how difficult getting a drug approved is one of the below links should work If anything the hard problems have grown harder as the full complexity of biology has come into focus. We have more things to worry about than we used to says Lowe. By the time a drug reaches trials it represents a billion dollars and a decade in the lives of hundreds if not thousands of scientists. One patient signs up. Then two. Months pass. Time crawls. The meter is always running Satler says. Its so expensive. If were doing this right if were building a learning system the next XX drugs"
@mike98572986 on X 2025-07-17 18:12:52 UTC XXX followers, XXX engagements
"$clpt $qure $rgnx Very good post by James Wilson big difference between those programs and the above companies the above companies are doing exactly this This contrasts with the relatively good safety profile of the broader portfolio of AAV products that deliver lower doses of systemic vector or use localized routes of administration. Overall low doses direct delivery As doctor Nicole Paulk has said Low doses + local admin = the way" @mike98572986 on X 2025-07-14 23:40:08 UTC XXX followers, 2689 engagements
"At the end of the day best thing we can all do is stay humble this game is extremely hard if Novartis can spend a billion dollars upfront and a couple months later find out that drug is likely useless do I believe that I can do the due diligence of a company like them Definitely not it is a perfect example of how tough biotech truly is. All each individual can do is what they are comfortable with understand the risks and go from there. I think anyone that has extreme confidence in anything is likely fooling ourselves. All we can do is make bets that make sense to each individual and live with" @mike98572986 on X 2025-07-17 17:40:08 UTC XXX followers, XXX engagements
"$clpt Bayer and Askbio For too long neurological and neurodegenerative diseases have been significantly underfunded despite the fact that they stand above cardiovascular disease as the top contributor to the global disease burden. In Europe brain disorders account for approximately XX% of the total disease burden and disorders of the nervous system are the largest cause of disability yet less than XX% of the total biomedical research budget is allocated to neurological research" @mike98572986 on X 2025-07-16 22:22:04 UTC XXX followers, XXX engagements
"$clpt Roche/Spark therapeutics study new research paper using clearpoint Overall the findings of this study will help guide the selection of the best retrograde AAV capsid for treatment of specific brain diseases. Vector was delivered into the bilateral putamen using intra-MRI guidance and the SmartFlow Neuro Cannula ClearPoint Neuro; Solano Beach CA Recent advances in neuroimaging techniques have helped delineate the structural and functional connectivity of the human brain and indicated that neurodegenerative diseases tend to target specific brain networks damaging their function.rAAV gene" @mike98572986 on X 2025-07-16 17:11:29 UTC XXX followers, XXX engagements
"Or we can also argue if there is another drug for hd that is coming out very near term that will be a threat (better numbers easier to do etc) that would be another good bear thesis imo" @mike98572986 on X 2025-07-17 16:55:22 UTC XXX followers, XXX engagements